ANDROTEST©:: A structured interview for the screening of hypogonadism in patients with sexual dysfunction

Introduction. Detecting hypogonadism, which is important in the general population, becomes crucial in patients with sexual dysfunctions, because hypogonadism can have a causal role for them and testosterone (T) substitution represents a milestone for the therapy. Aim. No inventories are available for the screening of hypogonadism in patients with sexual dysfunction. We wished to set up a brief structured interview providing scores useful for detecting hypogonadism defined as low total T (< 10.4 nmol/L, 300 ng/dL) in a symptomatic population (sexual dysfunction). Methods. A minimum set of items was identified within a larger structured interview through iterative receiver-operating characteristic curve analysis, with assessment of sensitivity and specificity for hypogonadism in a sample of 215 patients. Main Outcome Measures. Sensitivity and specificity were verified in a further sample of 664 patients. Correlation of test scores with prostate-specific antigen (PSA), testis volume, and others clinical and psychological parameters, was assessed for concurrent validity. Results. In the validation sample, the final 12-item version of the interview (ANDROTEST (C)) had a sensitivity and specificity of 68% and 65%, in detecting low total T (< 10.4 nmol/L) and of 71% and 65%, in the screening for low free T (< 37 pmol/L). Furthermore, patients with a pathological test (i.e., score > 8) showed higher prevalence of hypogonadism-related signs, such as lower testis volume and higher depressive symptoms. Finally, when only younger patients (< 54 years, which represents the median age of the sample) were considered, Log(10) [PSA] levels were significantly lower in those with ANDROTEST(C)score > 8. Conclusion. ANDROTEST(C) is a quick and easy-to-administer interview that provides scores for the screening of male hypogonadism in patients with sexual dysfunction.